Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391063 | 0.85 | CYP2C9 (0.50) | CNR1SLC6A4SLC6A3CASRCNR2 | |
| SCHEMBL390578 | 0.83 | ADRB2 (0.47) | CNR1MTNR1AMTNR1BBRD4SLC6A4 | |
| SCHEMBL8421133 | 0.83 | MTNR1A (0.72) | CNR1MTNR1AMTNR1BCASRCNR2 | |
| SCHEMBL3652339 | 0.80 | DRD2 (0.48) | CNR1MEN1KMT2ASMN1; SMN2DRD2 | |
| SCHEMBL11486796 | 0.78 | CNR1 (0.48) | CNR1MTNR1AMTNR1BBRD4CASR | |
| SCHEMBL16649689 | 0.78 | SLC6A4 (0.47) | SLC6A4SLC6A3ADRB2CYP2D6 | |
| SCHEMBL386863 | 0.78 | SLC6A4 (0.47) | SLC6A4SLC6A3ADRB2CYP2D6 | |
| SCHEMBL391960 | 0.77 | MTNR1A (0.50) | CNR1MTNR1AMTNR1B | |
| SCHEMBL11494345 | 0.75 | LTA4H (0.49) | CNR1MTNR1AMTNR1BSMN1; SMN2PPARG | |
| SCHEMBL17555372 | 0.74 | MAPT (0.42) | CNR2MEN1KMT2AL3MBTL1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252495-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2025-03-18 | — | — | US | disclosed |
| US-20240109902-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2024-04-04 | — | — | US | disclosed |
| US-11760760-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2023-09-19 | — | — | US | disclosed |
| US-11760760-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2023-09-19 | — | — | US | disclosed |
| US-11760760-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2023-09-19 | — | — | US | disclosed |
| US-20220220116-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| US-20220220116-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| US-11236095-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2022-02-01 | — | — | US | disclosed |
| US-11236095-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2022-02-01 | — | — | US | disclosed |
| US-20200239483-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2020-07-30 | — | — | US | disclosed |
| US-20120190679-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2012-07-26 | — | — | US | disclosed |
| US-8101623-B2 | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor | ASTRAZENECA AB (SE) | 2012-01-24 | — | — | US | disclosed |
| US-8101623-B2 | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor | ASTRAZENECA AB (SE) | 2012-01-24 | — | — | US | disclosed |
| US-8101623-B2 | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor | ASTRAZENECA AB (SE) | 2012-01-24 | — | — | US | disclosed |
| EP-2201012-A1 | PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS | AstraZeneca AB (SE) | 2010-06-30 | — | — | EP | disclosed |
| US-20090163524-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163524-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163524-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
| WO-2009047563-A1 | PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047563-A1 | PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252495-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | CNR1 1799/4885MTNR1A 2147/4885MTNR1B 988/4885 |
| US-20220220116-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | CNR1 1799/4885MTNR1A 2147/4885MTNR1B 988/4885 |
| US-20240109902-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | CNR1 1799/4885MTNR1A 2147/4885MTNR1B 988/4885 |
| US-20090163524-A1 | Novel Protein Kinase B Inhibitors - 060 | PRKAR2B, PRKCB, MAP3K20 | CNR1 1551/4885MTNR1A 2374/4885MTNR1B 1203/4885 |
| US-20200239483-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | CNR1 1799/4885MTNR1A 2147/4885MTNR1B 988/4885 |
| US-20120190679-A1 | Novel Protein Kinase B Inhibitors - 060 | PRKAR2B, PRKCB, MAP3K20 | CNR1 1551/4885MTNR1A 2374/4885MTNR1B 1203/4885 |
| US-11236095-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | CNR1 1799/4885MTNR1A 2147/4885MTNR1B 988/4885 |
| US-11760760-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | CNR1 1799/4885MTNR1A 2147/4885MTNR1B 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.